
Publication|Articles|May 1, 2003
The American Journal of Managed Care
- May 2003
- Volume 9
- Issue 5
Effect of Off-Label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience
Author(s)Darren Kocs, MD, MHSA, A. Mark Fendrick, MD
Advertisement
Articles in this issue
over 22 years ago
Lansoprazole Overutilization: Methods for Step-Down TherapyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5














































